Pathogenesis of vascular disease in hyperhomocysteinaemia

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 5, Issue 4, 1998, Pages 239-247

  Domagala, Teresa B ^a   Undas, Anetta ^a   Libura, Magdalena ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

arterial dilatation; atherosclerosis; endothelial dysfunction; homocysteine; lipid peroxidation; nitric oxide; proliferation of smooth muscle cells; prothrombotic state; thrombosis

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; THROMBOSIS; VASCULAR DISEASE;

ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; MUSCLE, SMOOTH, VASCULAR; RISK FACTORS; THROMBOSIS;

EID: 0344267633     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182679800500406     Document Type: Article

References (100)

1. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332–1339.
2. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488–500.
3. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801–809.
4. McCully KS. Vascular pathology of homocyst(e)inemia: Implications for the development of arteriosclerosis. Am J Pathol 1969; 56: 111–128.
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049–1057.
6. Stampfer MJ, Malinow MR, Willet WC. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877–881.
7. den Heijer M, Koster T, Bolm HJ, Bos GMJ, Briet E, Reitsma PH, et al Hyperhomocysteinemia as a risk factor for deep venous thrombosis. N Engl J Med 1996; 334: 759–762.
8. Cattaneo M, Martinelli I, Mannuci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974–975.
9. Simoni P, Prandoni P, Burlina A, Totmne D, Sardella C, Ferrari V, et al Hyperhomocysteinemia and deep-vein thrombosis. A case control study. Thromb Haemost 1996; 76: 883–886.
10. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113–121.
11. Harker LA, Slichter CR, Scott CR, Ross R. Homocysteinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537–543.
12. Harker LA, Ross R, Slichter CR, Scott CR. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–741.
13. Dudman NPB, Hicks C, Wang J, Wilcken DEL. Human arterial endothelial cell detachment in vitro: Its promotion by homocysteine and cysteine. Atherosclerosis 1991; 91: 77–83.
14. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1996; 338: 1042–1050.
15. Welch GN, Upchurch GR Jr., Loscalzo J. Hyperhomocystein(e)inemia and atherothrombosis. Ann NY Acad Sci 1997; 811: 48–58.
16. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5–7.
17. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995; 41: 361–366.
18. Misra HP. Generation of superoxide free radicals during the autooxidation of thiols. J Biol Chem 1974; 249: 2151–2155.
19. Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett 1982; 138: 33–36.
20. de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial dysfunction in homocystinuria. Eur J Clin Invest 1983; 13: 405–410.
21. Starkebaum G, Harlam JM. Endothelial cell injury due to cooper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370–1376.
22. Schoneich C, Dillinger U, von Bruchhausen F, Asmus KD. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals: Reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch Biochem Biophys 1992; 292: 456–467.
23. Harman LS, Carver DK, Schreiber J, Mason RP. One- and two-electron oxidation of reduced glutathione by peroxidases. J Biol Chem 1986; 261: 1642–1648.
24. Eling TE, Curtis JF, Harman LS, Mason RP. Oxidation of glutathione to its thiyl free radical metabolite by prostaglandin H synthase. A potential endogenous substrate for the hydroperoxidase. J Biol Chem 1986; 261: 5023–5028.
25. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1–30.
26. Stamler JM, Osborne JA, Jarali O, Rabbani LE, Mullins M, Singel D, et al Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308–318.
27. Stampler JS, Loscalzo J. Endothelium-derived relaxing factor modulates the atherothrombotic effects of homocysteine. J Cardiovasc Pharm 1992; 20 (suppl 12):S202–S204.
28. Thomas G, Skrinska VA, Lucas FV. The influence of glutathione and other thiols on human platelet aggregation. Thromb Res 1986; 44: 859–866.
29. Stamler JM, Cunningham M, Loscalzo J. Reduced thiols and the effect on intravenous nitroglicerin on platelet aggregation. Am J Cardiol 1988; 62: 377–380.
30. Jia Li, Furchgott FW. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharm Exper Ther 1993; 267: 371–378.
31. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radical Res Commun 1993; 18: 195–199.
32. Radi R, Beckman JS, Bush K, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitricoxide. J Biol Chem 1991; 266: 4244–4250.
33. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, et al Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. J Biol Chem 1994; 269: 26066–26075.
34. Upchurch∗ GR Jr., Welch GN, Fabian AJ, Pigazzi A, Keaney JF, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 1997; 132: 177–185.
35. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24–29.
36. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, et al Impaired endothelial function occurs in the systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854–858.
37. Joannides R, Haefeli WE, Under L, Richard V, Bakkali EH, Thuillez C, et al Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries ∗in vivo. Circulation 1995; 91: 1314–1319.
38. Woo KS, Chook P, Lolin Yl, Cheung ASP, Chan LT, Sun YY, et al Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542–2544.
39. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95: 1119–1121.
40. Krzanowski M, Domagala TB, Motyl A, Frolow M, Szczeklik A. Hyperhomocysteinemia following oral methionine load impairs endothelium-dependent arterial dilatation in atherosclerotic subjects but not in healthy controls [abstract]. Netherlands J Med 1998; 52 (suppl):S15.
41. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731–739.
42. Tsai JC, Perrela MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–6373.
43. Tsai JC, Wang H, Perrela MA, Yoshizumi M, Sibinga ES, Tan LC, et al Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146–153.
44. Lubec B, Labudova O, Hoeger H, Muehl A, Fang-Kircher S, Marx M, et al Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996; 94: 2620–2625.
45. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169–173.
46. Welch GN, Upchurch GR Jr., Farivar RS, Pigazzi A, Vu K, Brecher P, et al Homocysteine-induced nitric-oxide production in vascular smooth muscle cells by NF-KB dependent transcriptional activation of Nos2. Proc Assoc Am Phys 1998; 110: 22–31.
47. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–924.
48. Yla-Hertulla S, Paliński W, Rosenfeld ME, Parthasarathy S. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086–1095.
49. Kim K, Kim IH, Lee KY, Rhee SG, Stadtman ER. The isolation and purification of a specific ‘protector’ protein which inhibits enzyme inactivation by a thiol/Fe(∗lll)/O2 mixed-function oxidation system. J Biol Chem 1988; 263: 4704–4711.
50. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and -independent mechanisms. J Lip Res 1993; 34: 2051–2061.
51. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds to its recognition by the acetyl LDL receptor. Biochem Biophys Acta 1987; 917: 337–340.
52. Hirano K, Ogihara T, Miki M, Yasuda H, Tamai H, Kawamura N, et al Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radical Res 1994; 21: 267–276.
53. Brown MS, Goldstein JL. Lipoprotein metabolism in macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983; 52: 223–261.
54. Thien M. Thiol-dependent lipid peroxidation. Biochem Biophys Res Commun 1982; 107: 279–285.
55. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolaction of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 1994; 4: 70–77.
56. McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993; 23: 477–493.
57. Blom HJ, Engelen DPE, Boers GHJ, Stadhouders AM, Sengers RCA, De Abreu R, et al Lipid peroxidation in homocysteinaemia. J Inher Metab 1992; 15: 419–422.
58. Toborek M, Kopieczna-Grzebieniak E, Dróźdź M, Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 1995; 115: 217–224.
59. Domagala TB, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411–416.
60. Kritchevsky D. Dietary protein and experimental atherosclerosis. Ann NY Acad Sci 1993; 676: 180–187.
61. McCully KS. Homocysteine theory of arteriosclerosis development and current status. Atheroscler Rev 1983; 11: 157–246.
62. Rees MM, Rodgers GM. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337–359.
63. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997; 20: 307–315.
64. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine- induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909–1916.
65. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic homocysteine. J Clin Invest 1991; 88: 1900–1904.
66. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895–901.
67. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930–2936.
68. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327–1333.
69. Palareti G, Salardi S, Piazzi S, Legnani C, Poggi M, Grauso F, et al Blood coagulation changes in homocystinuria: Effects of pyridoxine and other specific therapy. J Pediatr 1986; 109: 1001–1006.
70. Munnich A, Saudubray JM, Dautzenberg MD, Parvy P, Ogier H, Girot R, et al Diet-responsive proconvertin (factor VII) deficiency in homocystinuria. J Pediatr 1983; 102: 730–734.
71. Ratnoff OD. Activation of Hageman factor by L-homocysteine. Science 1968; 162: 1007–1009.
72. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873–2879.
73. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, et al Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987–9993.
74. Lentz SR, Sadler E. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683–689.
75. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherosclerosis, and sulhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193–10197.
76. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381–1386.
77. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, et al Abnormally high thromboxane biosynthesis in homozygous homocystinuria: Evidence for platelet involvement and probucolo-sensitive mechanism. J Clin Invest 1993; 92: 1400–1406.
78. Durand P, Lussier-Cacan S, Blanche D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane synthesis and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157–1168.
79. van der Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, et al Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176–181.
80. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618–623.
81. van der Molen EF, Hiipakka MJ, van Lith-Zanders H, Boers GH, van den Heuvel LP, Monnens LA, et al Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine beta-synthase (CS) deficiency. Thromb Haemost 1997; 78: 827–833.
82. de Jong SC, Stehouwer CD, van der Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997; 78: 1332–1337.
83. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost 1997; 77: 466–471.
84. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Osterman H, et al Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: Relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1994; 72: 550–553.
85. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent thrombin generation after myocardial infarction. Arterioscler Thromb 1992; 12: 548–553.
86. Domagala B, Undas A, Jankowski M, Libura M, Szczeklik A. Thrombin generation in hyperhomocysteinemia before and after treatment with folic acid and vitamin B12. Thromb Haemost 1997; 77(suppl):530 (PS 2169).
87. Cedar H. DNA methylation and gene activity. Cell 1988; 53: 3–4.
88. Clarke S. Protein methylation. Curr Opin Cell Biol 1993; 5: 977–983.
89. Barber Jr., Clarke S. Inhibition of protein carboxyl methylation by S-adenosyl-L-homocysteine in intact erythrocytes. Physiological consequences. J Biol Chem 1984; 259: 7115–7122.
90. Wong H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, et al Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380–25385.
91. Sobotka-Briner C, Chelsky D. COOH-terminal methylation of lamin B and inhibition of methylation by farnesylated peptides corresponding to lamin B and other CAAX motif proteins. J Biol Chem 1992; 267: 12116–12122.
92. Xie H, Clarke S. Protein phosphatase 2A is reversibly modified by methyl esterification at its C-terminal leucine residue in bovine brain. J Biol Chem 1994; 269: 1981–1984.
93. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935–1942.
94. Kim WK, Pae Y-S. Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neuroscience Lett 1996; 216: 117–120.
95. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997; 94: 5923–5928.
96. Dalton ML, Gadson PF Jr., Wrenn RW, Rosenquist TH. Homocysteine signal cascade: Production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703–711.
97. Majors AK, Jacobsen DW, Pyeritz RF. Upregulation of collagen accumulation by homocysteine and its abrogation by heparin(s) [abstract]. Netherlands J Med 1998; 52 (suppl):S57.
98. Bescond A, Augier T, Chareyre C, Charpiot P, Garcon D. Homocysteine-induced elastolysis in arterial media: Activation of MMP2 [abstract]. Netherlands J Med 1998; 52 (suppl):S56–S57.
99. Guo XW, Dudman NPB. Homocysteine alters interactions between human leucocytes and vascular endothelial cells in vitro [abstract]. Netherlands J Med 1998; 52 (suppl):S58.
100. Jacobsen DW, Poddar R. Vascular dysfunction at the cellular level [abstract]. Netherlands J Med 1998; 52 (suppl):S1.